Clinical and molecular approaches to individualize antihypertensive drug therapy

Annals of Medicine

Volumn 44, Issue SUPPL. 1, 2012, Pages

  Hiltunen, Timo P ^a   Kontula, Kimmo ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Adrenergic beta 1 receptor antagonists; angiotensin II type 1 receptor blockers; calcium channel blockers; drug therapy; hypertension; pharmacogenetics; thiazides

Indexed keywords

AMLODIPINE; BISOPROLOL; HYDROCHLOROTHIAZIDE; LOSARTAN;

ACE GENE; ADD1 GENE; ADRB1 GENE; AGT GENE; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; MONOTHERAPY; PERSONALIZED MEDICINE; PHARMACOGENETICS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STK39 GENE; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIURETICS; HUMANS; HYPERTENSION; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84862524263     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2012.679960     Document Type: Review

References (29)

1. Attwood S, Bird R, Burch K, Casadei B, Coats A, Conway J, et al. Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. J Hypertens. 1994;12:1053-60. (Pubitemid 24294817)
2. Hiltunen TP, Suonsyrjä T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Strandberg T, et al. Predictors of antihypertensive drug responses: initial data from a placebocontrolled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). Am J Hypertens. 2007;20:311-8.
3. Lloyd-Jones DM, Evans JC, Larson MG, O' D onnell CJ, Roccella EJ, Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension. 2000;36:594-9.
4. Varis J, Savola H, Vesalainen R, Kantola I. Treatment of hypertension in Finnish general practice seems unsatisfactory despite evidence-based guidelines. Blood Press. 2009;18:62-7.
5. Deary AJ, Schumann AL, Murfet H, Haydock SF, Foo RS, Brown MJ. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens. 2002;20:771-7. (Pubitemid 34913723)
6. Suonsyrjä T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Donner K, Strandberg T, et al. Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study. J Hypertens. 2008;26:1250-6. (Pubitemid 351670518)
7. Laragh JH, Letcher RL, Pickering TG. Renin profiling for diagnosis and treatment of hypertension. JAMA. 1979;241:151-6.
8. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328:914-21. (Pubitemid 23086643)
9. Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ, Cushman WC, et al. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. JAMA. 1998;280:1168-72. (Pubitemid 28457807)
10. Mazeaud MM, Sang KH, Astarie C, Levenson J, Simon A, Devynck MA. Hypercholesterolemia modulates the effects of nitrendipine on blood pressure and platelet function in essential hypertension. J Cardiovasc Pharmacol. 1991;18(Suppl 10):S46-51.
11. Resnick LM, Nicholson JP, Laragh JH. Calcium, the renin-aldosterone system, and the hypotensive response to nifedipine. Hypertension. 1987;10:254-8. (Pubitemid 17127842)
12. Midtbø K, Hals O. Serum ionized calcium-a predictor of therapeutic response to slow calcium channel blockade in essential hypertension. Angiology. 1987;38:841-6.
13. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661-78.
14. Wang Y, O' C onnell JR, McArdle PF, Wade JB, Dorff SE, Shah SJ, et al. Whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc Natl Acad Sci U S A. 2009;106:226-31.
15. Org E, Eyheramendy S, Juhanson P, Gieger C, Lichtner P, Klopp N, et al. Genome-wide scan identifies CDH13 as a novel susceptibility locus contributing to blood pressure determination in two European populations. Hum Mol Genet. 2009;18:2288-96.
16. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet. 2009;41:677-87.
17. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009;41:666-76.
18. Suonsyrjä T, Hannila-Handelberg T, Fodstad H, Donner K, Kontula K, Hiltunen TP. Renin-angiotensin system and alpha-adducin gene polymorphisms and their relation to responses to antihypertensive drugs: results from the GENRES study. Am J Hypertens. 2009;22:169-75.
19. Suonsyrjä T, Donner K, Hannila-Handelberg T, Fodstad H, Kontula K, Hiltunen TP. Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment. Pharmacogenet Genomics. 2010;20:342-5.
20. Donner KM, Hiltunen TP, Suonsyrjä T, Hannila-Handelberg T, Tikkanen I, Antikainen M, et al. CYP2C9 genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men. J Hypertens. 2009;27:2001-9.
21. Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation. 2005;111:3374-83. (Pubitemid 40923390)
22. Davis BR, Arnett DK, Boerwinkle E, Ford CE, Leiendecker-Foster C, Miller MB, et al. Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. Pharmacogenomics J. 2007;7:112-22. (Pubitemid 46567143)
23. Brugts JJ, Isaacs A, de Maat MP, Boersma E, van Duijn CM, Akkerhuis KM, et al. A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. J Hypertens. 2011;29:509-19.
24. Donner KM, Hiltunen TP, Hannila-Handelberg T, Suonsyrjä T, Kontula K. STK39 variation predicts ambulatory blood pressure response to losartan in hypertensive men. Hypertension Res. 2012;35:107-14.
25. San-Cristobal P, Pacheco-Alvarez D, Richardson C, Ring AM, Vazquez N, Rafiqi FH, et al. Angiotensin II signaling increases activity of the renal Na-Cl cotransporter through a WNK4-SPAK-dependent pathway. Proc Natl Acad Sci U S A. 2009;106:4384-9.
26. Talati G, Ohta A, Rai T, Sohara E, Naito S, Vandewalle A, et al. Effect of angiotensin II on the WNK-OSR1/SPAKNCC phosphorylation cascade in cultured mpkDCT cells and in vivo mouse kidney. Biochem Biophys Res Commun. 2010;393:844-8.
27. Rafiqi FH, Zuber AM, Glover M, Richardson C, Fleming S, Jovanovi S, et al. Role of the WNK-activated SPAK kinase in regulating blood pressure. EMBO Mol Med. 2010;2:63-75.
28. Duarte JD, Lobmeyer MT, Wang Z, Chapman AB, Gums JG, Langaee TY, et al. Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide. Pharmacogenet Genomics. 2010;20:516-9.
29. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Pressor responses to antihypertensive drug types. Am J Hypertens. 2010;23:1031-7.